Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019

NEXT STORY
CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity
PREV STORY
Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biomaterials Market to Exhibit 12.2% CAGR and Reach USD 245.6 Billion till 2027; Increasing Number of Novel Product Launches to Skyrocket Demand: Fortune Business Insights™

author_avatar
NASDAQ Market News

Helsinn Investment Fund: Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology

author_avatar
NASDAQ Market News

MemoSurge Reviews – Negative Side Effects or Real Benefits?

author_avatar
NASDAQ Market News